CDNA logo

CareDx (CDNA) Company Overview

Profile

Full Name:

CareDx, Inc

Sector:

Healthcare

Country:

United States

IPO:

July 17, 2014

Indexes:

Not included

Description:

CareDx, Inc. is a leading precision medicine company focused on discovering, developing, and commercializing clinically differentiated, high-value medical solutions for transplant patients and caregivers. CareDx, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company also develops, manufactures, and markets products that increase the likelihood of successful transplantation by facilitating matching between donor and recipient stem cells and organs. Key products of CareDx, Inc. include: - AlloSure Kidney - a cell-free DNA obtained from the donor (dd-cfDNA) solution for kidney transplant patients - AlloMap Heart - a gene expression solution for patients who have undergone heart transplantation.

Key Details

Price

$21.40

Annual Revenue

$280.32 M(-12.89% YoY)

Annual EPS

-$3.54(-145.83% YoY)

Annual ROE

-54.98%

Beta

1.60

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 4, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 15, 25 Wells Fargo
Equal-Weight
Jan 14, 25 HC Wainwright & Co.
Neutral
Nov 5, 24 BTIG
Buy
Oct 22, 24 HC Wainwright & Co.
Neutral
Oct 16, 24 Goldman Sachs
Buy
Aug 27, 24 Wells Fargo
Underweight
Aug 19, 24 BTIG
Buy
Aug 1, 24 HC Wainwright & Co.
Neutral
Aug 1, 24 Goldman Sachs
Buy
Aug 1, 24 Craig-Hallum
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CDNA
zacks.comJanuary 14, 2025

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CareDx: Top Of My Shopping List For 2025
CareDx: Top Of My Shopping List For 2025
CareDx: Top Of My Shopping List For 2025
CDNA
seekingalpha.comDecember 25, 2024

CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competition from major players like Natera, and macroeconomic factors affecting the transplant market.

Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
CDNA
zacks.comDecember 3, 2024

Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
CDNA
zacks.comNovember 25, 2024

The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
CDNA
zacks.comNovember 15, 2024

The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
CDNA
seekingalpha.comNovember 4, 2024

CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CDNA
accesswire.comOctober 25, 2024

NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CDNA
prnewswire.comOctober 11, 2024

NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CDNA
businesswire.comOctober 11, 2024

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company's newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CDNA
accesswire.comSeptember 30, 2024

NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

FAQ

  • What is the ticker symbol for CareDx?
  • Does CareDx pay dividends?
  • What sector is CareDx in?
  • What industry is CareDx in?
  • What country is CareDx based in?
  • When did CareDx go public?
  • Is CareDx in the S&P 500?
  • Is CareDx in the NASDAQ 100?
  • Is CareDx in the Dow Jones?
  • When was CareDx's last earnings report?
  • When does CareDx report earnings?
  • Should I buy CareDx stock now?

What is the ticker symbol for CareDx?

The ticker symbol for CareDx is NASDAQ:CDNA

Does CareDx pay dividends?

No, CareDx does not pay dividends

What sector is CareDx in?

CareDx is in the Healthcare sector

What industry is CareDx in?

CareDx is in the Diagnostics & Research industry

What country is CareDx based in?

CareDx is headquartered in United States

When did CareDx go public?

CareDx's initial public offering (IPO) was on July 17, 2014

Is CareDx in the S&P 500?

No, CareDx is not included in the S&P 500 index

Is CareDx in the NASDAQ 100?

No, CareDx is not included in the NASDAQ 100 index

Is CareDx in the Dow Jones?

No, CareDx is not included in the Dow Jones index

When was CareDx's last earnings report?

CareDx's most recent earnings report was on Nov 4, 2024

When does CareDx report earnings?

The next expected earnings date for CareDx is Feb 28, 2025

Should I buy CareDx stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions